Therapeutic considerations of sarcopenia in heart failure patients

References

• Anker SD, Coats AJ, Morley JE, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle. 2014;5(1):1–3.
   Web of Science ®Google Scholar
• Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014;5:253–259.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1:129–133.
   PubMed Web of Science ®Google Scholar
• von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc. 2015;74(4):367–377.
   PubMed Web of Science ®Google Scholar
• Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34:512–519.
   PubMed Web of Science ®Google Scholar
• Hajahmadi M, Shemshadi S, Khalilipur E, et al. Muscle wasting in young patients with dilated cardiomyopathy. J Cachexia Sarcopenia Muscle. 2017;8(4):542–548.
   PubMed Web of Science ®Google Scholar
• Coats AJ, Clark AL, Piepoli M, et al. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J. 1994;72(2 Suppl):S36–S39.
   PubMedGoogle Scholar
• Morley JE, von Haehling S, Anker SD, et al. From sarcopenia to frailty: a road less traveled. J Cachexia Sarcopenia Muscle. 2014;5(1):5–8.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Ebner N, Dos Santos MR, et al. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol. 2017;14(6):323–341.
   PubMed Web of Science ®Google Scholar
• Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol. 1981;47:33–39.
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Tzortzis S, Triantafyllidi H, et al. Association of impaired left ventricular twisting-untwisting with vascular dysfunction, neurohumoral activation and impaired exercise capacity in hypertensive heart disease. Eur J Heart Fail. 2015;17:1240–1251.
   PubMed Web of Science ®Google Scholar
• Corrà U, Piepoli MF, Adamopoulos S, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the committee on exercise physiology and training of the heart failure association of the ESC. Eur J Heart Fail. 2014;16:929–941.
   PubMed Web of Science ®Google Scholar
• Khan H, Kunutsor S, Rauramaa R, et al. Cardiorespiratory fitness and risk of heart failure: a population-based follow-up study. Eur J Heart Fail. 2014;16:180–188.
   PubMed Web of Science ®Google Scholar
• Heckman GA, Tannenbaum C, Costa AP, et al. The journey of the frail older adult with heart failure: implications for management and health care systems. Rev Clin Gerontol. 2014;24:269–289.
   Google Scholar
• Drexler H, Riede U, Münzel T, et al. Alteration of skeletal muscle in chronic heart failure. Circulation. 1992;85:1751–1759.
   PubMed Web of Science ®Google Scholar
• Lang CC, Chomsky DB, Rayos G, et al. Skeletal muscle mass and exercise performance in stable ambulatory patients with heart failure. J Appl Physiol. 1997;82:257–261.
   PubMed Web of Science ®Google Scholar
• Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992;85:1364–1373.
   PubMed Web of Science ®Google Scholar
• Minotti JR, Pillay P, Oka R, et al. Skeletal muscle size: relationship to muscle function in heart failure. J Appl Physiol. 1993;75:373–381.
   PubMed Web of Science ®Google Scholar
• Cicoira M, Zanolla L, Franceschini L, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2001;37:2080–2085.
   PubMed Web of Science ®Google Scholar
• Lexell J, Taylor CC, Sjöström M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci. 1988;84:275–294.
   PubMed Web of Science ®Google Scholar
• Borkan GA, Hults DE, Gerzof SG, et al. Age changes in body composition revealed by computed tomography. J Gerontol. 1983;38:673–677.
   PubMedGoogle Scholar
• Konishi M, Ishida J, von Haehling S, et al. Nutrition in cachexia: from bench to bedside. J Cachexia Sarcopenia Muscle. 2016;7(2):107–109.
   PubMed Web of Science ®Google Scholar
• Von Haehling S, Steinbeck L, Doehner W, et al. Muscle wasting in heart failure: an overview. Int J Biochem Cell Biol. 2013;45(10):2257–2265.
   PubMed Web of Science ®Google Scholar
• Saitoh M, Dos Santos MR, Ebner N, et al. Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from studies investigating co-morbidities aggravating heart failure. Wien Klin Wochenschr. 2016;128(Suppl 7):497–504.
   PubMedGoogle Scholar
• Sandek A, Do Bowenehner W, Anker SD, et al. Nutrition in heart failure: an update. Curr Opin Clin Nutr MetabCare. 2009;12:384–391.
   PubMed Web of Science ®Google Scholar
• Boxer RS, Dauser DA, Walsh SJ, et al. The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. J Am Geriatr Soc. 2008;56:454–461.
   PubMed Web of Science ®Google Scholar
• Batsis JA, Mackenzie TA, Barre LK, et al. Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III. Eur J Clin Nutrit. 2014;68:1001–1007.
   PubMed Web of Science ®Google Scholar
• Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci. 2000;904:437–448.
   PubMed Web of Science ®Google Scholar
• Stephen WC, Janssen I. Sarcopenic-obesity and cardiovascular disease risk in the elderly. J Nutr Health Aging. 2009;13:460–466.
   PubMed Web of Science ®Google Scholar
• Hambrecht R, Schulze PC, Gielen S, et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2002;39:1175–1181.
   PubMed Web of Science ®Google Scholar
• Onder G, Liperoti R, Russo A, et al. Body mass index, free insulin-like growth factor I, and physical function among older adults: results from the ilSIRENTE study. Am J Physiol Endocrinol Metab. 2006;291:E829–E834.
   PubMed Web of Science ®Google Scholar
• Bacurau AV, Jannig PR, de Moraes WM, et al. Akt/mTOR pathway contributes to skeletal muscle anti-atrophic effect of aerobic exercise training in heart failure mice. Int J Cardiol. 2016;214:137–147.
   PubMed Web of Science ®Google Scholar
• Dalla Libera L, Ravara B, Volterrani M, et al. Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure. Am J Physiol Cell Physiol. 2004;286(1):C138–44.
   PubMed Web of Science ®Google Scholar
• Volterrani M, Rosano G, Iellamo F. Testosterone and heart failure. Endocrine. 2012;42(2):272–277.
   PubMed Web of Science ®Google Scholar
• Josiak K, Jankowska EA, Piepoli MF, et al. Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones. J Cachexia Sarcopenia Muscle. 2014;5:287–296.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114(17):1829–1837.
   PubMed Web of Science ®Google Scholar
• Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003;88(4):1478–1485.
   PubMed Web of Science ®Google Scholar
• Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br J Pharmacol. 2008;154:522–528.
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E601–E607.
   PubMed Web of Science ®Google Scholar
• Siriett V, Platt L, Salerno MS, et al. Prolonged absence of myostatin reduces sarcopenia. J Cell Physiol. 2006;209:866–873.
   PubMed Web of Science ®Google Scholar
• LeBrasseur NK, Schelhorn TM, Bernardo BL, et al. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci. 2009;64(9):940–948.
   PubMed Web of Science ®Google Scholar
• Léger B, Derave W, De Bock K, et al. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008;11:163–175B.
   PubMed Web of Science ®Google Scholar
• Gielen S, Sandri M, Kozarez I, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig exercise intervention in chronic heart failure and aging catabolism study. Circulation. 2012;125:2716–2727.
   PubMed Web of Science ®Google Scholar
• Serra-Prat M, Papiol M, Monteis R, et al. Relationship between plasma ghrelin levels and sarcopenia in elderly subjects: a cross-sectional study. J Nutr Health Ageing. 2015;19(6):669–672.
   PubMed Web of Science ®Google Scholar
• Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab. 2015;4:437–460.
   PubMed Web of Science ®Google Scholar
• Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009;64:1183–1189.
   PubMed Web of Science ®Google Scholar
• Kim TN, Park MS, Lim KI, et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf). 2013;78:525–532.
   PubMed Web of Science ®Google Scholar
• Schrager MA, Metter EJ, Simonsick E, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 1985;2007(102):919–925.
   Google Scholar
• Viña J, Borras C, Abdelaziz KM, et al. The free radical theory of aging revisited: the cell signaling disruption theory of aging. Antioxid Redox Signal. 2013;19:779–787.
   PubMed Web of Science ®Google Scholar
• Fulle S, Protasi F, Di Tano G, et al. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol. 2004;39:17–24.
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Ikeda H, Haramaki N, et al. Oxidative stress is related to exercise intolerance in patients with heart failure. Am Heart J. 1998;135:115–120.
   PubMed Web of Science ®Google Scholar
• Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin in Clini Nut Metab Care. 2010;13:225–229.
   PubMed Web of Science ®Google Scholar
• Hershko A, Ciechanover A. Mechanisms of intracellular protein breakdown. Annu Rev Biochem. 1982;51:335–364.
   PubMed Web of Science ®Google Scholar
• Attaix D, Aurousseau E, Combaret L, et al. Ubiquitin–proteasome-dependent proteolysis in skeletal muscle. Reprod Nutr Dev. 1998;38:153–165.
   PubMedGoogle Scholar
• Höllriegel R, Beck EB, Linke A, et al. Anabolic effects of exercise training in patients with advanced chronic heart failure (NYHA IIIb): impact on ubiquitin-protein ligases expression and skeletal muscle size. Int J Cardiol. 2013;167:975–980.
   PubMed Web of Science ®Google Scholar
• Han J, Kou X, Jia S, et al. Autophagy as a potential target for sarcopenia. J Cell Physiol. 2016;231(7):1450–1459.
   PubMed Web of Science ®Google Scholar
• Jannig PR, Moreira JB, Bechara LR, et al. Autophagy signaling in skeletal muscle of infarcted rats. PLoS One. 2014;9(1):e85820.
   PubMed Web of Science ®Google Scholar
• Marzetti E, Lees HA, Manini TM, et al. Skeletal muscle apoptotic signaling predicts thigh muscle volume and gait speed in community-dwelling older persons: an exploratory study. PLoS One. 2012;7:e32829.
   PubMed Web of Science ®Google Scholar
• Filippatos GS, Kanatselos C, Manolatos DD, et al. Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia. Int J Cardiol. 2003;90:107–113.
   PubMed Web of Science ®Google Scholar
• Malafarina V, Uriz-Otano F, Iniesta R, et al. Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review. J Am Med Dir Assoc. 2013;14:10–17.
   PubMed Web of Science ®Google Scholar
• Murphy CH, Oikawa SY, Phillips SM. Dietary protein to maintain muscle mass in aging: a case for per-meal protein recommendations. J Frailty Aging. 2016;5(1):49–58.
   PubMedGoogle Scholar
• Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013;14:542–559.
   PubMed Web of Science ®Google Scholar
• Aquilani R, Opasich C, Gualco A, et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur J Heart Fail. 2008;10:1127–1135.
   PubMed Web of Science ®Google Scholar
• Rozentryt P, von Haehling S, Lainscak M, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010;1:35–42.
   PubMed Web of Science ®Google Scholar
• Girón MD, Vílchez JD, Salto R, et al. Conversion of leucine to β-hydroxy-β-methylbutyrate by α-keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubes. J Cachexia Sarcopenia Muscle. 2016;7(1):68–78.
   PubMed Web of Science ®Google Scholar
• Holeček M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions. J Cachexia Sarcopenia Muscle. 2017;8:529–541.
   PubMed Web of Science ®Google Scholar
• van Dronkelaar C, van Velzen A, Abdelrazek M, et al. Minerals and sarcopenia; the role of calcium, iron, magnesium, phosphorus, potassium, selenium, sodium, and zinc on muscle mass, muscle strength, and physical performance in older adults: a systematic review. J Am Med Dir Assoc. 2018;19(1):6-11. e3.
   Web of Science ®Google Scholar
• Wicherts IS, van Schoor NM, Boeke AJ, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab. 2007;92:2058–2065.
   PubMed Web of Science ®Google Scholar
• Jiang WL, Gu HB, Zhang YF, et al. Vitamin D supplementation in the treatment of chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol. 2016;39:56–61.
   PubMed Web of Science ®Google Scholar
• Beaudart C, Buckinx F, Rabenda V, et al. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014;99:4336–4345.
   PubMed Web of Science ®Google Scholar
• Bauer JM, Verlaan S, Bautmans I, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2015;16:740–747.
   PubMed Web of Science ®Google Scholar
• Forbes SC, Little JP, Candow DG. Exercise and nutritional interventions for improving aging muscle health. Endocrine. 2012;42:29–38.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Conraads V, Corrà U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13:347–357.
   PubMed Web of Science ®Google Scholar
• Cunha TF, Bacurau AV, Moreira JB, et al. Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure. PLoS One. 2012;7:e41701.
   PubMed Web of Science ®Google Scholar
• Smart NA, Steele M. The effect of physical training on systemic proinflammatory cytokine expression in heart failure patients: a systematic review. Congest Heart Fail. 2011;17:110–114.
   PubMedGoogle Scholar
• Lenk K, Erbs S, Höllriegel R, et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. Eur J Prev Cardiol. 2012;19:404–411.
   PubMed Web of Science ®Google Scholar
• Wenz T, Rossi SG, Rotundo RL, et al. Increased muscle PGC-1a expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci USA. 2009;106:20405–20410.
   PubMed Web of Science ®Google Scholar
• Brown JC, Harhay MO, Harhay MN. Physical activity, diet quality, and mortality among sarcopenic older adults. Aging Clin Exp Res. 2017;29(2):257–263.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. gov. [cited 2017 Aug 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT02582138?term=SPRINTT&recrs=a&rank=1
   Google Scholar
• Maggioni AP, Anker SD, Dahlström U, et al. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013 Oct;15(10):1173–1184.
   PubMed Web of Science ®Google Scholar
• Zhou LS, Xu LJ, Wang XQ, et al. Effect of angiotensin-converting enzyme inhibitors on physical function in elderly subjects: a systematic review and meta-analysis. Drugs Aging. 2015;32:727–735.
   PubMed Web of Science ®Google Scholar
• Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361(9363):1077–1083.
   PubMed Web of Science ®Google Scholar
• Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol. 2006;106(3):319–322.
   PubMed Web of Science ®Google Scholar
• Drescher C, Konishi M, Ebner N, et al. Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. J Cachexia Sarcopenia Muscle. 2015;6:303–311.
   PubMed Web of Science ®Google Scholar
• Springer J, Tschirner A, Haghikia A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J. 2014;35:932–941.
   PubMed Web of Science ®Google Scholar
• Pötsch MS, Tschirner A, Palus S, et al. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle. 2014;5:149–158.
   PubMed Web of Science ®Google Scholar
• Stewart Coats AJ, Ho GF, Prabhash K, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016;7(3):355–365.
   PubMed Web of Science ®Google Scholar
• Clark AL, Coats AJ, Krum H, et al. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. J Cachexia Sarcopenia Muscle. 2017 Feb 27. DOI:10.1002/jcsm.12191
   Web of Science ®Google Scholar
• Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919–927.
   PubMed Web of Science ®Google Scholar
• Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010;56:1310–1316.
   PubMed Web of Science ®Google Scholar
• Dos Santos MR, Sayegh AL, Bacurau AV, et al. Effect of exercise training and testosterone replacement on skeletal muscle wasting in patients with heart failure with testosterone deficiency. Mayo Clin Proc. 2016;91(5):575–586.
   PubMed Web of Science ®Google Scholar
• Papanicolaou DA, Ather SN, Zhu H, et al. A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging. 2013;17(6):533–543.
   PubMed Web of Science ®Google Scholar
• Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–345.
   PubMed Web of Science ®Google Scholar
• Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–531.
   PubMed Web of Science ®Google Scholar
• White HK, Petrie CD, Landschulz W, et al. Capromorelin Study Group. Effects of an oral growth hormone scretagogue in older adults. J Clin Endocrinol Metab. 2009;94:1198–1206.
   PubMed Web of Science ®Google Scholar
• Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fractures: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53:183–189.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674–3679.
   PubMed Web of Science ®Google Scholar
• McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83–90.
   PubMed Web of Science ®Google Scholar
• Becker C, Lord SR, Studenski SA, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015;3(12):948–957.
   PubMed Web of Science ®Google Scholar
• Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with bimagrumab: results from a phaseⅡ, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017;65:1988–1995. DOI:10.1111/jgs.14927
   PubMed Web of Science ®Google Scholar
• Testa G, Cacciatore F, Galizia G, et al. Waist circumference but not body mass index predicts long-term mortality in elderly subjects with chronic heart failure. J Am Geriatr Soc. 2010;58:1433–1440.
   PubMed Web of Science ®Google Scholar
• Tian S, Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int. 2016;16:155–166.
   PubMed Web of Science ®Google Scholar
• Rolland Y, Lauwers-Cances V, Cristini C, et al. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women. The EPIDOS (EPIDemiologie de l’OSteoporose). Am J Clin Nutr. 2009;89:1895–1900.
   PubMed Web of Science ®Google Scholar
• Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults. The health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61:1059–1064.
   PubMed Web of Science ®Google Scholar
• De Schutter A, Lavie CJ, Kachur S, et al. Body composition and mortality in a large cohort with preserve ejection fraction: untangling the obesity paradox. Mayo Clin Proc. 2014;89(8):1072–1079.
   PubMed Web of Science ®Google Scholar
• Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27:1–15.
   PubMed Web of Science ®Google Scholar
• Lupón J, González B, Santaeugenia S, et al. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. Rev Esp Cardiol. 2008;61(8):835–842.
   PubMed Web of Science ®Google Scholar
• Cacciatore F, Abete P, Mazzella F, et al. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest. 2005;35:723–730.
   PubMed Web of Science ®Google Scholar